A phase II study of ABI-007 in combination with Ramucirumab in patients with unresectable/recurrent gastric cancer refractory to prior chemotherapy containing fluoropyrimidines
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2016
At a glance
- Drugs Paclitaxel (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 09 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2016 New trial record
- 17 Feb 2016 Status changed from not yet recruiting to recruiting.